Bone Biologics Corp Warrants
BBLGW
2 hedge funds and large institutions have $690K invested in Bone Biologics Corp Warrants in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
25% more capital invested
Capital invested by funds: $551K → $690K (+$139K)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$132K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $684K | -$132K | -5,571 | -16% |
|
|
2
UBS Group
Zurich,
Switzerland
| $5.63K | +$2.9K | +122 | +41% |
|
BBLGW Hedge Fund Activity: Q1 2026 in Review
2 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q1 2026, worth a combined $690K — up 25% from $551K a quarter earlier.
Fund positioning in BBLGW was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $2.9K. The largest seller was Citadel Advisors, cutting an estimated $132K.
- 2 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $690K of Bone Biologics Corp Warrants stock for Q1 2026, up 25% quarter-over-quarter.
- 0 funds opened new Bone Biologics Corp Warrants positions in Q1 2026 and 0 closed out.
- The largest Bone Biologics Corp Warrants buyer in Q1 2026 was UBS Group, an estimated $2.9K added.
- The largest Bone Biologics Corp Warrants seller in Q1 2026 was Citadel Advisors, an estimated $132K sold.
Based on aggregated 13F filings for Q1 2026.